Endocrine gland neoplasm

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This study tests a radioactive drug called 177Lu-DOTA-EB-TATE in 18 adults with a rare thyroid cancer (Hurthle cell) that has spread and not responded to standard radioactive iodine treatment. The drug is designed to seek out and attach to cancer cells. Participants will receive …

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This study tests whether giving two drugs (ateganosine and cadonilimab) before surgery can safely shrink liver tumors in people with resectable hepatocellular carcinoma. About 60 participants will receive either one or both drugs before their operation. The main goal is to see if…

This study tests whether a personalized nursing program can prevent acute kidney injury (AKI) in people with liver cancer who undergo interventional therapy. Researchers first use a prediction model to classify patients into low, moderate, or high risk for AKI. Then, they provide…

This phase II trial investigates whether adding SHR-8068 to a two-drug regimen (adebrelimab and apatinib) can improve outcomes for people with liver cancer that can be surgically removed but has a moderate-to-high risk of coming back. Participants receive the drug combination bef…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy (gemcitabine and cisplatin) in people with a rare, advanced liver cancer called combined hepatocellular-cholangiocarcinoma that cannot be removed by surgery or has spread. Ab…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 538 people with advanced biliary tract cancer that has worsened after prior treatments. The goal is to see if the new drug helps people live longer. The study is not yet recruiting.

This study tests whether combining two drugs—ASTX727 (a pill) and retifanlimab (given through a vein)—can shrink tumors and control advanced Merkel cell cancer in people whose disease has worsened after standard immunotherapy. About 31 adults with stage III or IV Merkel cell canc…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This study investigates whether regular blood tests can detect liver cancer earlier in people with type 2 diabetes who also have significant liver scarring. Participants are randomly assigned to either a surveillance group receiving specialized blood tests every six months or a s…

This study tests a surgery called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with certain pancreatic tumors who are at high risk for a dangerous leak after standard surgery. The procedure removes the entire pancreas and transplants the insulin-making…

This trial tests a treatment called Yttrium-90 radiation segmentectomy for people with liver cancer that can't be removed by surgery. Tiny radioactive beads are injected into the blood supply of the tumor to deliver targeted radiation. The study will enroll 64 participants to see…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This study tests a combination of targeted radiation (SBRT) and an experimental drug called QL1706 in 36 adults with advanced liver cancer that has worsened after one prior treatment. The radiation is given to liver tumors over five sessions, followed by QL1706 infusions every th…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This study tests a radiation treatment called SIRT (selective internal radiation therapy) using tiny radioactive beads delivered directly to liver tumors. The goal is to shrink tumors enough so that patients with liver cancer can qualify for a liver transplant or have surgery to …

This study tests a new planning method called multicompartment dosimetry (MCD) for TheraSphere, a treatment that delivers tiny radioactive beads to liver tumors. The goal is to give a higher radiation dose to the tumor while protecting healthy liver. Researchers will enroll 140 p…

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…

This phase 1 trial tests a radioactive drug called 211At-MABG in 16 adults with advanced neuroendocrine cancers, including pheochromocytoma and paraganglioma. The drug delivers radiation directly to cancer cells that show up on a special scan. The main goal is to see if the treat…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-phase trial tests whether giving advanced thyroid cancer patients a personalized mix of already-approved drugs, chosen based on their tumor's genetic profile, is feasible and safe. Ten patients with no other treatment options will receive individualized drug combinatio…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…

This study tests a treatment called NRT6003, which delivers tiny radioactive beads directly to liver tumors through a blood vessel. It is for people with liver cancer that has already been treated but not cured. The goal is to see if this single session of internal radiation can …

This study compares two surgical approaches for unilateral thyroid cancer: a newer, scar-free endoscopic technique through the armpit versus standard open neck surgery. Researchers will track complications, recovery time, and patient satisfaction in 400 adults aged 18-70 with ear…

This study tests a new drug (BL-M14D1) combined with an approved immunotherapy (atezolizumab) in 36 adults with extensive-stage small cell lung cancer that has no standard treatment. The goal is to see if the combination can shrink tumors and control the disease. Participants mus…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This phase II trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—in 30 adults with advanced biliary tract cancer whose first treatment stopped working. The goal is to see if the combo can shrink tumors and improve sur…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study tests an experimental drug (PD-1/IL-2 bispecific antibody) given before a second surgery in 30 adults whose liver cancer returned early after initial curative surgery. The goal is to see if the drug can shrink or kill more cancer cells before the operation, potentially…

This study tests whether a common antibiotic for women's UTIs, fosfomycin-trometamol, works well for men with urinary tract infections. Current treatments can have serious side effects and increase antibiotic resistance. The trial will enroll 138 men in primary care and monitor f…

This trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer mor…

This phase 2 trial tests a drug called sacituzumab tirumotecan in people with neuroendocrine prostate cancer, a rare and aggressive form that has progressed after platinum-based chemotherapy. The drug is given by IV infusion three times per 42-day cycle. The study measures how ma…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This phase II trial tests whether giving a mix of immunotherapy (durvalumab), chemotherapy (cisplatin and gemcitabine), and possibly a targeted drug (futibatinib) before surgery can improve outcomes for patients with resectable intrahepatic cholangiocarcinoma, a type of bile duct…

This phase 2 trial tests a new drug called AUR103 calcium in 30 people with advanced neuroendocrine tumors that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug twice daily unt…

This trial tests a drug called HRX215 in 80 adults with colorectal cancer that has spread to the liver. Before surgery to remove liver tumors, patients often get a procedure (PVE) that blocks blood flow to the tumor area to encourage the healthy part of the liver to grow. HRX215 …

This Phase 2 trial tests whether adding lurbinectedin to paclitaxel works better than paclitaxel alone for people with advanced small cell lung cancer that has returned after first treatment. About 69 adults will be randomly assigned to one of two groups. The study measures how m…

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can help people with advanced bile duct cancer live longer without their cancer growing. About 123 adults with untreated, inoperable bile duct cancer will be randomly assigned to …

This study tests a combination of two drugs, QL1706 and anlotinib, for people with advanced small cell lung cancer who have already tried at least two prior treatments. The goal is to see if the combination helps control the cancer and extends survival. About 120 adults aged 18 t…

This phase 2 trial tests whether combining two drugs, lomustine and anlotinib, can shrink tumors or slow disease in people with extensive-stage small cell lung cancer that has not responded to at least two prior treatments. About 46 participants will receive the drug combination …

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This Phase 3 trial tests whether adding obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to get either the combo or chemo alone. Obrixtamig is designed to help the immune sy…

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests whether adding tarlatamab to durvalumab after standard chemotherapy and radiation can delay cancer return and extend life in people with limited-stage small cell lung cancer. Tarlatamab works by helping immune cells recognize and attack cancer cells. About 430 pa…

This early-phase trial tests a personalized cell therapy (rapcabtagene autoleucel) in 20 adults with large B-cell lymphoma who still have traces of cancer after initial treatment. The goal is to see if the therapy can make those traces disappear, potentially lowering the risk of …

This early-phase trial tests a new drug called AB801, which blocks a protein (AXL) that helps cancers grow and resist treatment. It is given alongside chemotherapy and immunotherapy to people with bile duct or pancreatic cancer that is either borderline resectable, locally advanc…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This study tests a combination of two immunotherapy drugs (iparomlimab and toripalimab) plus bevacizumab and chemotherapy as a first treatment for advanced biliary tract cancer. It involves 32 adults aged 18-75 who have not had prior treatment for their advanced cancer. The goal …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a combination of four drugs (epalrestat, HAIC, donafenib, and tislelizumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery and who also have diabetes. The goal is to see if this approach can control the cancer for at …

This study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a …

This early study tests if a new, needle-based treatment using brief electric pulses can safely destroy certain pancreatic tumors without surgery. The treatment aims to spare healthy tissue nearby. About 12 adults with specific pancreatic cysts or low-grade tumors will be enrolled…

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This study tests whether giving a combination of chemotherapy directly into the liver (HAIC) plus two drugs (camrelizumab and apatinib) before and after surgery can prevent liver cancer from returning in high-risk patients. About 208 people with resectable liver cancer and high-r…

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This study tests an experimental drug called DXC006 combined with either an immunotherapy drug (toripalimab) or standard chemotherapy (carboplatin or cisplatin) in 200 people with small cell lung cancer. The goal is to find the safest dose and see if the combination shrinks tumor…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This study tests whether removing only the cancerous part of the thyroid and nearby lymph nodes on one side is safe and effective for sporadic medullary thyroid cancer. Currently, all patients get the entire thyroid removed, which requires lifelong hormone pills and carries highe…

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This phase 2 trial tests whether alternating between two chemotherapy regimens (mFOLFOX and mFOLFIRI) works better than using just one (mFOLFOX) as a second-line treatment for advanced biliary tract cancer. The study will enroll 130 adults whose cancer has progressed after first-…

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…

This Phase 2 trial tests whether combining lurbinectedin (Zepzelca) with durvalumab (Imfinzi) as maintenance therapy can delay cancer growth in people with extensive-stage small-cell lung cancer whose disease has not worsened after initial chemotherapy plus durvalumab. About 50 p…

This study tests whether a newer, shorter metal stent works better than a standard plastic stent for opening blocked bile ducts in people with pancreatic cancer who need surgery. About 116 adults with operable or locally advanced pancreatic cancer and high bilirubin levels will b…

This phase 2 trial tests two oral drugs, lenvatinib and regorafenib, in 146 adults with advanced liver cancer that cannot be surgically removed and has worsened after initial immunotherapy. The study has two parts: one for patients with better liver function and one for those wit…

This Phase 3 trial tests a new drug, BL-M07D1, against standard chemotherapy in about 400 people with a specific type of advanced bile duct cancer (HER2-positive) that has stopped responding to platinum-based chemo. The goal is to see if BL-M07D1 can help people live longer. Part…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…

This study tests whether adding a special thermal therapy (which freezes and heats tumors) to standard targeted therapy and immunotherapy can help people with advanced liver cancer that cannot be removed by surgery. About 166 participants will be randomly assigned to receive eith…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This study tests a new drug called ZG006 against standard chemotherapy for people with advanced neuroendocrine carcinoma, a type of cancer. About 240 adults who have already had other treatments will be randomly assigned to receive either ZG006 or a chemotherapy chosen by their d…

This study tests if adding a targeted drug (becotatug vedotin) to standard chemotherapy and immunotherapy helps shrink tumors better than standard treatment alone in people with advanced bile duct cancer that has a specific gene change (EGFR mutation). About 164 adults with this …

This study tests a new drug combination for people with metastatic solid tumors that lack a gene called MTAP. The drugs, BMS-986504 and pemetrexed, aim to stop cancer cells from growing. The trial will check safety and how well the combo works in 72 participants.

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This phase 2 trial tests whether giving a combination of chemotherapy (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) before surgery can reduce tumor cells in patients with bile duct cancer at high risk of recurrence. About 34 adults aged 18-80 with resectabl…

This trial is testing a new way to treat intermediate and advanced liver cancer. It combines two liver-directed procedures (HAIC and TACE) with two drugs (apatinib and camrelizumab) to see if this approach works better than other combinations. The study will involve 315 adults wi…

This trial tests whether bendamustine causes fewer severe side effects than the standard fludarabine/cyclophosphamide combination when given before CAR-T cell therapy for B-cell lymphoma. About 92 people will be randomly assigned to one of the two chemotherapy regimens. The main …

This early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This phase 2 trial tests a combination of two targeted drugs (donafenib and sintilimab) plus chemotherapy delivered directly to the liver as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study will enroll 90 participants and measur…

This study tests a new treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. It combines low-dose radiation to the chest with an immunotherapy drug (adebrelimab) and chemotherapy, followed by maintenance immunotherapy for up to t…

This phase 3 trial tests whether adding chemotherapy after surgery can prevent aggressive pancreatic neuroendocrine tumors from coming back. About 300 patients will either receive active surveillance alone or 6 cycles of capecitabine-temozolomide pills plus surveillance. The stud…

This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This Phase 2 trial tests whether adding epcoritamab, an immune-boosting drug, to standard R-CHOP chemotherapy can safely treat newly diagnosed aggressive B-cell lymphoma. About 20 adults with certain lymphoma types will receive the combination. The main goal is to check for a sid…

This early-stage trial tests a new RNA-based drug called YMN-A02 in 10 people with advanced liver cancer that has stopped responding to standard treatments. The drug is designed to boost the immune system by blocking two cancer defenses at once. The main goal is to check safety a…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This phase 2 trial tests a drug called sacituzumab tirumotecan (Sac-TMT) in 30 people with advanced thymic carcinoma that has worsened after platinum-based chemotherapy. Participants receive the drug every two weeks, and doctors will check how well it shrinks tumors and monitor s…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

This study tests whether adding radiation to immunotherapy and chemotherapy can help people with advanced small-cell lung cancer that has spread to the liver. It includes 30 adults aged 18-75 whose cancer did not respond to or stopped responding to prior treatments. The goal is t…

This study looks at people with papillary thyroid cancer tumors 2 to 4 cm who are having thyroid surgery. Half will also have nearby neck lymph nodes removed, and half will not. The goal is to see if removing these nodes lowers the chance of cancer coming back or persisting, and …

This early-phase study tests a new experimental drug (BRII-5395) combined with two approved cancer treatments (sintilimab and bevacizumab) in about 21 adults with advanced liver cancer linked to chronic hepatitis B. The main goal is to check safety and find the right dose, while …

This study looks at two types of metal stents (partially covered vs. bare) used to open blocked bile ducts in people with incurable cancer. The goal is to see which stent keeps the duct open longer and causes fewer problems. Sixty adults who already have a drainage tube will be r…

This early-stage trial tests a new vaccine that targets a specific protein found only in fibrolamellar liver cancer cells. The vaccine is combined with three other drugs to boost the immune system and block cancer growth. About 27 people with advanced disease who have already tri…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This phase 2 study tests whether adding the experimental drug zanzalintinib to the approved immunotherapy durvalumab can help people with advanced liver cancer live longer. Participants have already responded to an initial treatment of tremelimumab plus durvalumab and are now on …

This study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This study tests whether a combination of two drugs—adebrelimab (given by IV) and S-1 (taken as pills)—can help prevent bile duct cancer from returning after surgery. About 40 adults who had their cancer fully removed will receive the treatment for about 4 months and be monitored…

This study tests whether adding a new drug, obrixtamig, to standard chemotherapy can help people with a rare and aggressive lung cancer called large-cell neuroendocrine carcinoma (LCNEC). The trial will include 75 adults with advanced LCNEC that cannot be cured by surgery. Resear…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This study tests whether a drug called adebrelimab can help keep limited-stage small cell lung cancer from coming back after initial chemotherapy and radiation. About 200 adults aged 18-75 with untreated, limited-stage disease will be randomly assigned to receive either standard …

This phase 2 trial tests a combination of low-dose bevacizumab (a blood vessel growth blocker) and adebrelimab (an immunotherapy) along with two liver-directed procedures (TACE and HAIC) as a first treatment for people with unresectable hepatocellular carcinoma, a type of liver c…

This early-phase study will test whether adding peginterferon alfa-2b to standard antiviral drugs can help prevent hepatitis B-related liver cancer from coming back after surgery. About 156 adults aged 18 to 65 will receive either the combination or antivirals alone. Researchers …

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This phase 2 trial tests a drug called FHD-286 in 20 people with a specific type of small-cell lung cancer that has a marker called POU2F3. Participants take the drug by mouth once daily in 21-day cycles. The main goal is to see if the drug can shrink tumors.

This study looks back at how well a type of targeted radiation therapy (PRRT) works for people with advanced pheochromocytoma and paraganglioma, rare tumors of the adrenal glands. Researchers will analyze data from about 210 patients treated in Italy over 24 years. The goal is to…

This early-stage trial tests a new drug called BL0020 combined with the immunotherapy Toripalimab in 33 people whose extensive-stage small cell lung cancer has returned after initial treatment. The main goal is to check safety and find the right dose, while also seeing if the com…

This study tests a drug called tarlatamab in 35 adults with small cell lung cancer that has spread to the brain but is not causing symptoms. The goal is to see if the drug can shrink or control these brain tumors. Participants must have already had standard chemotherapy and be in…

This early-phase study tests whether adding an experimental drug (DSP-0390) to the immunotherapy atezolizumab can safely help prevent extensive stage small cell lung cancer from growing back after initial chemotherapy and immunotherapy. About 20 adults whose cancer did not worsen…

This study tests whether adding Babao Dan Capsule (a traditional Chinese medicine) to standard antiviral treatment can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis who are at high risk. About 1,034 adults aged 18-65 with a specific TCM …

This study tests a device that keeps donor livers cool and oxygenated before transplant, aiming to reduce early liver problems. About 215 first-time liver transplant patients will receive a liver preserved with this method. The goal is to see if it lowers the risk of early graft …

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This early-phase trial will test a new type of cell therapy called Meta10-GPC3 CAR-T in 27 people with advanced liver cancer that cannot be surgically removed. The treatment involves taking a patient's own immune cells, modifying them to recognize and attack liver cancer cells, a…

This phase II trial tests a combination of low-dose bevacizumab and atezolizumab (immunotherapy drugs) plus targeted chemotherapy delivered directly to the liver (TACE-HAIC) as a first treatment for people with unresectable hepatocellular carcinoma. About 38 participants will rec…

This phase 2 trial tests a combination of nab-paclitaxel (a chemotherapy drug) and local radiation therapy for people with extensive-stage small-cell lung cancer whose disease has worsened after initial treatment. The study aims to see if this combo can improve progression-free s…

This study tests a new combination of drugs (BL-B01D1 and tislelizumab) against standard chemotherapy plus tislelizumab as the first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer. About 562 adults with good performance status will join th…

This phase 2 trial is testing a powerful combination of treatments for people with limited-stage small cell lung cancer (LS-SCLC) who have not had prior therapy. Participants will receive an immunotherapy drug (benmelstobart), an anti-angiogenic pill (anlotinib), standard chemoth…

This study tests an experimental drug called WGI-0301 combined with lenvatinib in 80 people with advanced liver cancer who have already tried one treatment. The goal is to see if the combination is safe, tolerable, and shrinks tumors. It is an open-label, non-placebo trial across…

This study tests a new treatment for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment before. It combines an immunotherapy drug (benmelstobart), a targeted therapy (anlotinib), and chemotherapy, followed by chest radiation. The goal is to see…

This study looks at whether starting denosumab early, along with a standard immunotherapy, can prevent bone problems like fractures or spinal cord compression in people with liver cancer that has spread to the bones. About 50 adults with liver cancer and bone metastases will be r…

This study looks at whether surgically removing the main liver tumor, followed by standard immune-based drug therapy, can help people with liver cancer that has spread to other organs live longer. About 280 adults with resectable liver tumors and at least one metastasis will be r…

This phase 3 trial tests whether adding targeted radiation or other local treatments to standard drug therapy can help people with liver cancer that has spread to a few spots outside the liver. All 400 participants first receive a combination of the immunotherapy sintilimab and t…

This study tests a combination of three drugs—firsekibart, tislelizumab, and lenvatinib—in people with advanced liver cancer that has a specific genetic change called a TP53 mutation. Participants must have already tried immunotherapy without success. The goal is to see if this d…

This phase 2 trial tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few other spots and no longer responds to first-line treatment. The goal is to see if this triple therapy can slow …

This study tests whether a combination of two drugs, zanzalintinib and cemiplimab, can help people with a rare and fast-growing thyroid cancer called anaplastic thyroid cancer live longer. The goal is to extend average survival by about 4 months. The trial will include 12 adults …

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This study tests whether giving a mix of chemotherapy, immunotherapy, and targeted therapy before surgery can reduce the risk of liver cancer returning in patients with high-risk features. About 100 participants will either receive the combination treatment followed by surgery, o…

This phase 2 trial tests VG2025, a modified herpes virus that targets and kills cancer cells while boosting the immune system, in 30 people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer). The virus is injected directly into tumors every four weeks. Ear…

This study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in people with extensive-stage small cell lung cancer whose cancer has already been treated. The goal is to see if the combination can shrink tumors. About 33 adults aged 18 to 75 with good perfor…

This study tests a drug called sacituzumab tirumotecan in people with two rare cancers: adenoid cystic carcinoma (a type of salivary gland cancer) and papillary thyroid carcinoma that have returned or spread. About 68 participants will receive the drug through an IV twice a month…

This phase II trial tests an experimental drug called SHR-A1904 in 23 people with advanced neuroendocrine carcinoma whose cancer has worsened after standard chemotherapy. The study measures how many patients have their tumors shrink or disappear, how long they live without the ca…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This phase II trial tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can reduce the risk of liver cancer returning in patients with early-stage disease and narrow surgical margins. Sixty participants will be randomly assigned to receive the drug combina…

This study tests whether the drug regorafenib can help people with advanced liver cancer whose disease got worse after treatment with lenvatinib. About 24 adults will receive regorafenib and be monitored for how long their cancer stays under control and for side effects. The goal…

This phase 2 trial tests the cancer pill regorafenib in 20 adults with advanced liver cancer and moderate liver dysfunction (Child-Pugh B) whose disease worsened after first-line immunotherapy. Participants take regorafenib daily for 3 weeks on, 1 week off, until the cancer progr…

This study tests two drugs together—pucotenlimab (which helps the immune system fight cancer) and becotatugvedotin (which targets and kills cancer cells)—in people with advanced bile duct cancer that has not responded to prior treatment. The main goal is to see how many patients'…

This study tests a new treatment for people with advanced liver cancer that cannot be surgically removed. The treatment combines a type of internal radiation (Y-90) with two immunotherapy drugs (durvalumab and tremelimumab) and a targeted therapy pill (zanzalintinib). The goal is…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 30 adults with early-stage liver cancer (stage IB or IIA) will receive…

This phase 2 trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy), and standard chemotherapy—as a first treatment for people with large-cell neuroendocrine carcinoma of the lung or similar cancers outside the lung. The study ai…

This Phase 2 trial tests a combination of two drugs, utidelone and bevacizumab, with or without a third drug called etoposide, in 56 patients with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and improve outcomes. Parti…

This trial tests a new treatment called SHB-02-CD19, which uses a patient's own immune cells engineered to attack cancer cells that have a protein called CD19. It is for children and adults with B-cell cancers (like leukemia or lymphoma) that have come back or not responded to at…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This study tests a new drug called WGI-0301 combined with the immunotherapy nivolumab in people with advanced liver or kidney cancer. The goal is to see if the combination is safe and can shrink tumors. About 230 adults aged 18 to 75 will take part, and the study does not use a p…

This study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…

This study tests whether combining local tumor treatments (TACE or ablation) with immunotherapy drugs (sintilimab and ipilimumab) before surgery can lower the chance of liver cancer coming back. It involves 105 adults with resectable liver cancer at intermediate-to-high risk of r…

This Phase 2 trial tests whether adding the immunotherapy drug envafolimab to standard chemotherapy (gemcitabine plus cisplatin) helps people with advanced biliary tract cancers live longer without their cancer growing. About 126 adults who have not had prior treatment for advanc…

This pilot study tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) after a standard liver cancer procedure called Y90 radioembolization can help control hepatocellular carcinoma. About 20 adults with liver cancer will be randomly assigned to one …

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This study tests whether combining two drugs, tislelizumab and nintedanib, can help control limited-stage small cell lung cancer after standard chemoradiation. About 20 adults with good performance status will receive this consolidation therapy. The goal is to delay cancer progre…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This study tests a combination of two drugs (vebecotototo and putli monoclonal antibodies) in 44 people with advanced bile duct cancer that has a specific marker (EGFR) and has not responded to prior treatment. The goal is to see if the combination can shrink tumors and control t…

This phase II trial tests whether combining the immunotherapy drug adebrelimab with chemotherapy and radiation before surgery can help shrink tumors in people with locally advanced thymic carcinoma. About 31 participants will receive the treatment, then have surgery if the tumor …

This study tests a new approach for people with liver cancer that cannot be removed by surgery. The treatment combines a procedure to grow the healthy part of the liver, chemotherapy directly into the liver, and two drugs (tislelizumab and lenvatinib) to shrink the tumor. The goa…

This study tests whether adding a traditional Chinese medicine called Biejia-Ruangan compound to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis. About 1,034 high-risk adults (based on a special score) will b…

This study tests whether combining two drugs—camrelizumab (an immunotherapy) and rivoceranib (a targeted therapy)—with or without local treatments like surgery or radiation can shrink tumors in people with advanced liver cancer that has spread to the lungs. About 32 participants …

This early-phase trial tests a new drug called MRG006A, combined with immunotherapy and targeted therapy, in 160 people with advanced hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery. The study aims to check safety, find the right dose, and se…

This study tests a combination of the targeted drug limertinib plus chemotherapy (etoposide and carboplatin) in 30 people with a specific type of lung cancer. These patients have a mutation in the EGFR gene and their cancer has changed from non-small cell to small cell lung cance…

This early-phase study tests a new drug called SYS6090 combined with standard chemotherapy or other drugs in about 600 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combinations are safe and if they can shrink tumors. The trial is not …

This phase 3 study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be enrolled. The main goal is to see if this app…

This Phase 2 trial tests whether adding personalized radiotherapy (PULSAR) and fecal microbiota transplants (FMT) to standard targeted-immunotherapy can reverse resistance in advanced liver cancer. About 64 patients whose cancer stopped responding to first-line treatment will be …

This study tests a new, affordable type of radioactive microsphere for treating liver cancer that cannot be removed by surgery. The microspheres are delivered directly to the tumor through a blood vessel, delivering radiation to kill cancer cells. The trial will enroll 18 adults …

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel…

This study tests whether 6 cycles of chemotherapy before surgery is better than 3 cycles for people with a rare type of thymus gland tumor. About 116 adults with locally advanced but removable tumors will be randomly assigned to one of the two treatment groups. The goal is to see…

This phase II trial tests whether combining an immunotherapy drug (PD-L1 inhibitor) with chemotherapy and radiation can shrink advanced bile duct tumors enough to allow a liver transplant. The study will enroll 25 adults with locally advanced perihilar cholangiocarcinoma that can…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This study tests whether giving the immunotherapy drug atezolizumab before liver surgery can strengthen the body's immune response against liver cancer (hepatocellular carcinoma). About 30 patients will receive two doses before their operation. Researchers hope this approach migh…

This early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This small study will test a new device that uses heat to destroy liver tumors in 20 people who cannot have surgery. The main goal is to see if the device is safe and how well it works at shrinking tumors after one month. Researchers will also check how the treatment affects the …

This study tests whether using a gentle suction tube (negative-pressure drainage) is better than placing a small plastic tube (stent) in the pancreas to prevent pancreatitis after removing tumors from the duodenum. About 132 adults with early-stage tumors will be randomly assigne…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests whether giving more radioactive iodine can help people with differentiated thyroid cancer whose tumor marker (thyroglobulin) is high but whose scans show nothing. One hundred adults who have already had their thyroid removed and one round of radioactive iodine wi…

This study tests whether adding the drug Mitazalimab to standard chemotherapy helps people with advanced bile duct cancer live longer. About 160 adults whose cancer has spread or cannot be removed will receive either chemo alone or chemo plus Mitazalimab. Researchers will check s…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This phase II trial tests two drugs—anlotinib and benmelstobart—as a second-line treatment for people with advanced or metastatic differentiated thyroid cancer that has not responded to first-line therapy. The study will enroll 23 participants and measure how many see their tumor…

This study tests a combination of chemotherapy delivered directly to the liver, an oral targeted drug, and an immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors. The trial will enroll 30…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This phase 2 trial tests whether adding branched-chain amino acids (BCAAs) to the drugs lenvatinib and pembrolizumab helps adults with unresectable liver cancer live longer without their cancer worsening. About 234 participants will be randomly assigned to receive the standard tw…

This early-stage trial tests a new drug called BL0020 in 48 adults whose lung cancer has changed from one type (non-small cell) to another (small cell) after standard treatment. The drug is given by IV every three weeks. The goal is to see if it can shrink tumors and control the …

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This study looks at 100 liver cancer patients whose tumors shrank or disappeared after initial therapy. It compares two follow-up options: surgery to remove any remaining cancer, or continuing medication (maintenance therapy). The goal is to see which approach better prevents the…

This study will enroll 40 people with high-risk differentiated thyroid cancer who need radioactive iodine therapy. After stopping their own thyroid hormones, participants will receive either standard levothyroxine alone or levothyroxine plus liothyronine. The goal is to see which…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This study tests a combination of two drugs (adebrelimab and oral etoposide) in elderly or frail patients with small cell lung cancer. The goal is to see if this treatment can slow down the cancer's growth and improve outcomes. About 47 participants will receive the treatment, an…

This study tests a new combination of drugs (SH006 plus chemotherapy) against the standard drug regorafenib in 120 people with advanced liver cancer that has not responded to immunotherapy. The goal is to see if the new combo can slow cancer growth or improve survival. Participan…

This study compares two strategies for using levothyroxine to suppress TSH in patients with advanced thyroid cancer that cannot be fully removed. The standard approach keeps TSH very low (below 0.1), but this can cause side effects. The trial will test if a slightly higher TSH ta…

This study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in 30 people with extensive-stage small cell lung cancer whose disease got worse after initial chemotherapy plus immunotherapy. The goal is to see if the combo can shrink tumors or slow cancer gro…

This study looks at whether combining a special surgery (electrocautery) with heated chemotherapy given directly into the chest can help people with thymic tumors that have spread to the chest lining. About 70 participants will receive the treatment and be followed for up to 3 ye…

This study compares surgery alone to surgery plus heated chemotherapy (HITOC) for people with thymic tumors that have spread to the lining of the chest. About 202 participants will be randomly assigned to one of the two groups. The goal is to see if adding HITOC helps keep the ca…

This early-phase study tests the safety of a new cell therapy called B7-H3 CAR T cells for children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to target a protein (B7-H3) …

This early-phase study tests a new drug called JSKN027 in 250 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study focuses on colorectal, lun…

This phase 3 trial compares two treatments for small liver cancer (tumors 5 cm or smaller): surgery to remove the tumor or a precise, high-dose radiation therapy called SBRT. About 312 adults with a single liver tumor will be randomly assigned to one of the two treatments. The st…

This Phase 2 trial tests whether adding the immunotherapy drug adebrelimab to standard chemoradiotherapy, followed by maintenance adebrelimab, can help control limited-stage small cell lung cancer. About 76 adults aged 18-75 with untreated localized disease will be enrolled. The …

This study will test whether a deep learning computer model can help doctors decide which liver cancer patients should receive immunotherapy (PD-1 inhibitors) after surgery to prevent the cancer from returning. About 300 patients who have had their liver cancer completely removed…

This phase 2 trial tests a four-drug maintenance therapy for people with extensive small cell lung cancer that has responded to initial treatment. The combination includes liposome irinotecan, platinum chemotherapy, an immune checkpoint inhibitor (toripalimab), and an anti-angiog…

This study compares two ways to remove small rectal neuroendocrine tumors (less than 1 cm). The new method, called modified double snare EMR, is expected to be just as effective as the standard ESD procedure but with shorter operation time, fewer complications, and lower cost. Ab…

This study looks back at medical records of 300 people with liver cancer that could not be removed by surgery. About 100 received a combination of local treatments (like TACE or radiation) plus targeted drugs and immunotherapy, aiming to shrink tumors enough for surgery. The othe…

This early-phase study tests a new treatment called QH103 for adults with B-cell lymphoma that has come back or not responded to standard therapy. QH103 uses specially engineered immune cells (CAR-γδT cells) from healthy donors to target and kill cancer cells. The main goals are …

This early-phase trial tests a new drug called TPD3310 in 112 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive weekly injections over 28-day cycl…

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…

This study tests a three-part treatment for people with liver cancer that has spread into the main vein of the liver (portal vein tumor thrombus). Participants will receive radiation therapy, followed by two drugs (tislelizumab and anlotinib) to boost the immune system and block …

This study tests whether growing a patient's tumor cells in the lab (as organoids) can help doctors choose the most effective drugs after liver cancer surgery. 56 adults with high-risk features will have their tumor tested against several approved drugs. The goal is to see if thi…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This study tests whether growing a patient's tumor cells in the lab (called organoids) and testing different drugs on them can help doctors choose the most effective treatment for advanced liver cancer that cannot be removed by surgery. About 94 adults aged 18-70 will either rece…

This study looks at people with limited-stage small cell lung cancer whose disease is under control after chemoradiation. A special blood test (MRD) checks for leftover cancer signals. Those with positive results get a combination of immunotherapy and anti-angiogenic drugs to try…

This study tests whether injecting a blue dye called mitoxantrone hydrochloride into the thyroid during robotic surgery helps surgeons see and remove cancer-affected lymph nodes while avoiding the parathyroid glands. 114 people with papillary thyroid cancer will be randomly assig…

This study tests a new way to choose cancer drugs for people with advanced biliary tract cancer that cannot be removed by surgery. Doctors will take a small sample of the tumor, grow it in the lab, and test different drugs to see which one works best. The goal is to see if this p…

This study tests a new combination of four treatments for people with liver cancer that cannot be removed by surgery and who also have high blood pressure in the liver (portal hypertension). The goal is to see if adding a blood-pressure drug (carvedilol) to standard cancer therap…

This phase II trial tests a personalized approach for people with advanced liver cancer that cannot be removed by surgery. Researchers will classify each patient's tumor by its fatty acid degradation (FAD) subtype and assign either a drug combination (camrelizumab plus apatinib) …

This study tests a new treatment for people with extensive-stage small cell lung cancer who have not had treatment before. The approach combines the drug bemotuzumab with standard chemotherapy and another drug called anlotinib, followed by chest radiation. The goal is to see if t…

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests a new combination of treatments for people with a specific liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The treatment includes chemotherapy delivered directly to the liver, along with two oral and intravenous drugs. The goal i…

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This phase II trial tests whether giving the immunotherapy drug sintilimab along with targeted radiation before surgery can lower the risk of liver cancer returning. About 110 patients with resectable liver cancer will be randomly assigned to receive the combination therapy befor…

This early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This study tests whether blocking the artery that feeds a bile duct tumor before surgery can make it possible to remove the cancer safely. It includes 33 adults with advanced bile duct cancer that currently cannot be operated on. The main goal is to see how many patients are aliv…

This study tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy and chest radiation can help people with extensive-stage small cell lung cancer live longer without their cancer growing. About 46 adults aged 18-75 who have not had pr…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This study compares two treatment combinations for advanced liver cancer that cannot be removed by surgery. One group gets TACE (a procedure that blocks blood flow to the tumor and delivers chemo directly) plus immunotherapy and a targeted drug. The other group gets HAIC (a conti…

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This study tests a new drug, sacituzumab tirumotecan, in 38 people with advanced thymic epithelial tumors that have worsened after at least one prior treatment. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The goal is to see if it can shrink tu…

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This study tests whether adding two immunotherapy drugs (zimberelimab and domvanalimab) to standard chemotherapy (FOLFIRI) helps people with a rare, fast-growing neuroendocrine cancer live longer. About 122 adults whose cancer has worsened after first treatment will take part. Th…

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…

This phase 2 trial tests a combination of sintilimab (an immunotherapy), bevacizumab (a targeted therapy), and chemotherapy (albumin-bound paclitaxel plus gemcitabine) as a first treatment for people with advanced bile duct cancer that cannot be surgically removed. The study aims…

This study tests whether combining two powerful treatments—glofitamab and CAR-T therapy—can help people with a high-risk, hard-to-treat type of large B-cell lymphoma that has come back or not responded to prior treatment. About 24 adults will receive the combination and be monito…

This Phase 3 trial tests a new daily pill, TT-00420, against standard chemotherapy in 138 adults with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or mutation) and has worsened after first treatment. The study compares how long the cancer stays under…

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This phase 2 trial tests the drug lenvatinib as a first treatment for 50 adults with advanced liver cancer (HCC) who cannot have surgery or other curative treatments. The goal is to see if lenvatinib can control the cancer and improve survival. Participants must have measurable t…

This study tests a combination of three drugs—ivarmacitinib, camrelizumab, and apatinib—in 65 people with advanced liver cancer that has stopped responding to initial immunotherapy. The goal is to see if this triple therapy can shrink tumors or slow disease progression. Participa…

This study looks at whether combining local treatments (like targeted radiation or chemo beads) with newer drugs (anti-VEGF/TKIs and immune checkpoint inhibitors) can shrink liver tumors enough for patients to qualify for a transplant. Researchers will review records of 300 patie…

This study tests whether combining a liver-directed procedure (TACE) with an oral triple-drug cocktail works better than TACE plus standard targeted therapy and immunotherapy for people with liver cancer that cannot be surgically removed. About 222 participants will be randomly a…

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests whether taking a probiotic (Lactobacillus reuteri) before surgery can improve the effects of immunotherapy in people with liver cancer. About 40 adults with resectable liver cancer will either receive the probiotic plus immunotherapy or immunotherapy alone before…

This study will follow 1,200 people with extensive-stage small cell lung cancer who are starting treatment with toripalimab plus chemotherapy. Researchers will track how long patients live without their cancer progressing and overall survival, using real-world data from medical r…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This phase 2 trial tests the drug golidocitinib in 16 people with advanced lung cancer who have severe blood problems caused by immunotherapy. The goal is to see if the drug can safely improve blood counts and reduce symptoms. Participants take the drug until their blood levels r…

This trial investigates whether a special PET imaging tracer called [18F]FTT can help predict how well people with newly diagnosed bile duct cancer (cholangiocarcinoma) will respond to standard chemotherapy. The tracer binds to a protein called PARP1, which some tumor cells produ…

This early-phase trial will test a new radioactive tracer called [68Ga]Ga-PentixaFor in 15 people with metastatic small cell lung cancer. The goal is to see if this PET-CT scan can find tumors as well as the standard FDG PET-CT scan, both at diagnosis and when the disease gets wo…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study will test an artificial intelligence system that screens for breast, liver, kidney, and bladder cancers using standard CT scans taken for other reasons. Researchers plan to enroll 100,000 participants to see if the AI can catch tumors earlier and help doctors reduce mi…

This study compares two devices (EYEMAX and SPYGLASS) used to take tissue samples from the bile duct to diagnose cancer. About 120 adults with bile duct narrowing will be randomly assigned to one device. The goal is to see which tool gives more accurate cancer diagnoses.

This study will compare a new radioactive tracer, 18F-AmBF3TATE, to the standard tracer 68Ga-DOTATATE for PET scans in people with neuroendocrine tumors. The goal is to see if the new tracer is as good or better at finding tumors. About 51 participants will receive both tracers a…

This study looks at whether a genetic test called Thyroid GuidePx® can help doctors and patients with papillary thyroid cancer make better treatment choices. About 85 adults with early-stage thyroid cancer will take the test before surgery. Researchers will see if the test result…

This study compares two contrast-enhanced ultrasound scoring systems (LI-RADS and ESCULAP) to see which one better detects recurrent liver cancer in 105 patients who have had surgery for hepatocellular carcinoma. The goal is to improve diagnostic accuracy for new liver lesions. P…

This study tests whether a special ultrasound technique, called contrast-enhanced subharmonic ultrasound, can predict if chemotherapy is working for stomach cancer that has spread to the liver. Currently, doctors wait about 2 months for CT or MRI scans to see tumor shrinkage. Thi…

This study will test whether using a contrast agent called Sonazoid during ultrasound can find early-stage liver cancer better than standard ultrasound alone. About 556 adults with liver cirrhosis will be scanned every 4 to 6 months. The goal is to see if this method catches more…

This study tests a special ultrasound technique called contrast-enhanced subharmonic ultrasound to see if it can predict whether chemotherapy is working for colorectal cancer that has spread to the liver. Currently, doctors wait about 2 months for CT or MRI scans to see if tumors…

This study tests a new imaging method called 68Ga-NYM207 PET/CT to see if it can safely and accurately detect liver cancer (hepatocellular carcinoma). About 100 adults with suspected or known liver cancer will receive the scan. The goal is to improve how doctors find and monitor …

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study tests whether a special PET scan (18FET) can find small pituitary tumors that standard MRI scans miss. About 30 adults with suspected hormone-secreting pituitary tumors will receive the scan. If it works, it could help doctors decide on surgery or radiation without nee…

This study is testing a new blood test that looks for specific DNA changes (methylation) to monitor if liver cancer comes back after treatment. Researchers will enroll 162 adults with liver cancer who have had surgery, transplant, ablation, or chemoembolization. The test's accura…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This study looks at whether low-dose CT scans can help find lung cancer early in people aged 40 to 80 who have never smoked. About 2,500 participants will fill out questionnaires, give blood and urine samples, and have lung function tests and CT scans. Researchers will track how …

This study will use a special MRI machine to scan the liver for phosphorus and sodium signals in people with liver cancer and healthy volunteers. The goal is to see if these scans can tell the difference between cancerous and healthy tissue. 100 participants will be enrolled to t…

This early study will test a special imaging agent that targets a protein found on liver cancer cells. Six people with suspected or confirmed liver cancer will receive a low-dose radioactive tracer and then have a SPECT-CT scan. The goal is to see how the tracer moves through the…

This study tests a special imaging scan (Tc-GSA SPECT/CT) to see if it can predict liver failure after surgery for liver tumors. About 192 adults in Denmark will receive the scan before their operation. The goal is to compare this new method with standard tests and find the best …

This study tests a new type of PET scan (XH06 PET/CT or PET/MR) to see if it can diagnose liver cancer better than enhanced MRI. About 150 adults with suspected or confirmed liver cancer will get both scans, and results will be checked against tissue samples. The goal is to find …

This study tests whether measuring certain hormones in a blood sample can accurately identify which patients with primary aldosteronism (a common cause of high blood pressure) have a curable adrenal tumor. Currently, diagnosis often requires an invasive procedure called adrenal v…

This study will test a new type of PET scan using a radioactive tracer called 18F-Octreotide in 152 people with or suspected of having neuroendocrine tumors. The goal is to see if this scan can more accurately locate tumors, guide treatment decisions, and help predict how the dis…

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …

This phase II trial tests whether a low dose of the cancer drug erlotinib can prevent liver cancer in 60 adults with advanced liver fibrosis or cirrhosis. Participants will take either erlotinib or a placebo daily for a set period. The study will measure changes in a blood protei…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether taking a low-dose aspirin (100 mg) every day can prevent liver cancer in people with cirrhosis, a condition that raises cancer risk. About 890 adults from Australian hospitals will take aspirin or a placebo for 4 years while continuing their regular check…

This study tests whether a natural supplement called SAMe can help prevent liver cancer in people with advanced fatty liver disease (MASLD) and cirrhosis. About 94 adults will receive either SAMe or a placebo for 12 months. Researchers will measure changes in a blood test that pr…

This study in Zimbabwe will screen women of childbearing age and high school students for HPV and Hepatitis B, then offer vaccines to those who are eligible. It also includes cognitive behavioral therapy for mental health issues. The goal is to see if this combined approach can p…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This pilot trial tests whether adding emotional support to a cancer information website helps young adults (ages 20-39) with thyroid, melanoma, or testicular cancer feel less worried and distressed. 142 participants will either get general cancer info or the same info plus person…

This study explores whether a personalized music therapy session, called music-assisted relaxation and imagery (MARI), can reduce pain and change gene activity in people recovering from open surgery for stomach, pancreas, bile duct, liver, or peritoneal cancer. Participants will …

This study compares two ways to drain blocked bile ducts in people with cancer near the liver. One method places a tube across the blockage into the intestine, while the other uses a metal stent that stops short of the intestine. The goal is to see which approach causes fewer com…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study is testing a new web-based program designed to help people with pancreatic cancer manage stress and symptoms. Sixty participants will complete weekly one-hour online sessions for ten weeks, learning relaxation, coping, and communication skills. The goal is to see if th…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This early study tests an augmented reality (AR) system that overlays a tumor's image onto the liver during keyhole surgery. Six adults scheduled for liver tumor removal will participate. The goal is to see if the AR guidance helps surgeons remove tumors more completely and safel…

This study tests whether scheduled meditation using the Headspace app can improve recovery after pancreatectomy (surgery to remove part of the pancreas). Seventy patients will be asked to meditate regularly before and after surgery, and researchers will track pain, anxiety, sleep…

This study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…

This study tests whether giving lidocaine through a vein during and after liver surgery can reduce side effects like nausea, vomiting, and breathing problems caused by opioid painkillers. About 312 adults having planned open liver surgery will be randomly assigned to receive eith…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This study tests whether offering free rideshares, hotel stays, and meal delivery helps low-income liver cancer patients start treatment sooner. About 75 uninsured or underinsured adults with liver cancer will be randomly assigned to receive these social supports plus usual patie…

This Phase 2 trial tests whether a drug called nanocrystalline megestrol acetate can help people with advanced liver cancer who are losing weight and appetite. About 88 patients will receive either the drug or a placebo for 12 weeks while also getting standard cancer therapy. The…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study tests if health and wellness coaching helps people with papillary or follicular thyroid cancer follow their treatment plans and live healthier lives. Twenty adults who have had their thyroid removed and take daily thyroid medication will work with a coach to set goals …

This study is testing a program called Care and Connect, where trained volunteers provide support and information to people with lung cancer. The goal is to see if this program helps reduce distress and makes it easier for patients to get the care they need. About 50 adults with …

Low-risk thyroid cancer grows very slowly and has a 99% survival rate, but choosing among three treatment options can be stressful. This study gives patients a decision aid pamphlet right after diagnosis, before they see a surgeon. The pamphlet explains the options and lists ques…

This study tests a web-based program designed to help advanced cancer patients manage symptoms like depression, pain, fatigue, and sleep problems, while also supporting their caregivers. The program combines online tools with guidance from healthcare professionals. Researchers wi…

This study tests whether ondansetron, a drug typically used for nausea, can lower the risk and severity of side effects from immunotherapy in people with liver cancer. About 134 patients will receive ondansetron alongside their standard cancer treatment. The goal is to see if thi…

This study tests if inflating a small balloon in the stomach during surgery can prevent nausea, vomiting, and slow stomach emptying after pancreatic tumor removal. About 70 adults will be randomly assigned to get the balloon procedure or standard surgery. Researchers will track r…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether a probiotic called Clostridium butyricum CBM588 can reduce diarrhea and improve quality of life in people who have had their pancreas removed due to cancer or other growths. About 158 patients will take either the probiotic or a placebo for three months a…

This study tests whether a brief video can help people receiving radioiodine treatment for thyroid conditions feel less distressed and better manage side effects and safety rules. About 80 adults with hyperthyroidism or thyroid cancer will watch either a supportive video or a neu…

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This study looks at whether adding a special form of megestrol acetate to standard treatment can help improve appetite and body weight in people with advanced liver cancer who are experiencing cachexia (severe weight loss and muscle wasting). About 68 participants will be randoml…

This study looks at whether adding a special behavioral support program to standard medical care can help people with liver cancer that cannot be removed by surgery. About 193 adults will be split into two groups: one gets the support program (including in-person sessions and a W…

This trial tests a new way to place plastic stents in the bile duct for people with jaundice caused by cancer near the liver. The standard method places the stent across the bile duct opening, while the new method places it above the opening without cutting the muscle. The study …

This study looks at whether warming the contrast dye to body temperature (37°C) before injecting it during an ERCP procedure can lower the chance of infection (cholangitis) in people with hilar cholangiocarcinoma (a type of bile duct cancer). About 100 adults aged 18-90 who need …

This study explores whether a special imaging technique called parenchymal blood volume (PBV) imaging can detect changes in blood flow within liver tumors after giving a drug called nitroglycerin. The drug is commonly used for heart conditions but may temporarily increase blood f…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study uses blood tests (liquid biopsies) to track how small cell lung cancer changes during chemotherapy and immunotherapy. Researchers will analyze DNA from blood samples taken before, during, and after treatment in 50 patients. The goal is to understand why some cancers be…

This study will examine whether certain workplace chemicals or tasks increase the risk of biliary tract and pancreatic cancers. Researchers will compare detailed work histories of 210 cancer patients from two earlier trials with healthy volunteers. The goal is to identify occupat…

This observational study will use bedside ultrasound to measure the diaphragm—the main breathing muscle—in 120 adults with liver cirrhosis and compare them to healthy volunteers. Researchers want to see if cirrhosis weakens the diaphragm and if removing fluid from the belly impro…

This study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…

This study looks at how to safely place a breathing tube in people with acromegaly, a condition that can cause changes in the face and airway. It compares two methods: direct laryngoscopy and video laryngoscopy. The goal is to find which method gives a better view of the airway a…

This study aims to create a score that predicts the risk of infection within 30 days after a liver transplant. Researchers will collect blood samples from 279 liver transplant patients before and after surgery to measure immune markers. The goal is to combine these markers with o…

This study tests whether a digitally supported prehabilitation program is feasible for patients awaiting major surgery for cancers of the pancreas, liver, stomach, or esophagus. The program includes supervised exercise, nutritional counseling, psychological support, and digital t…

This study will collect and analyze medical records from about 4,000 adults diagnosed with liver cancer (hepatocellular carcinoma) in Middle Eastern and North African countries between 2015 and 2023. Researchers want to understand what causes the cancer, how it is treated, and wh…

This study will test whether doctors can quickly and accurately monitor minimal residual disease (tiny amounts of cancer left after treatment) in people with aggressive B-cell lymphoma. Researchers will use blood tests to look for tumor DNA and PET scans to see if results can be …

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study will analyze medical records of over 4,000 people newly diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the U.S. Researchers aim to understand which treatments are used, in what order, and how long patients stay on them. The goal is to describe…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study tests a computer vision model called PTAIR that helps surgeons identify parathyroid glands and recurrent laryngeal nerves during endoscopic thyroid surgery. About 100 adults with thyroid disease will take part. The model's ability to spot these structures will be compa…

This study looks back at data from 562 people who received a liver transplant for liver cancer (hepatocellular carcinoma) at hospitals in France, Canada, and Belgium. The goal is to create a better scoring system that considers tumor shrinkage before transplant, cancer growth whi…

This study will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug tarlatamab. Researchers will analyze the samples to learn more about how the drug works, who might benefit most, and how to predict side effects like cytokine rele…

This study looks at whether giving patients clear, standardized instructions before and after pituitary surgery can improve their recovery. Researchers will compare hospital stay length, complication rates, and unplanned readmissions in 102 adults having elective surgery. The goa…

This study looks at how a special program, called the Geriatric Surgery Verification Program, works at the James Cancer Hospital. The program helps doctors and nurses better care for patients aged 65 and older who need cancer surgery. It includes checking for age-related issues l…

This study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …

This study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…

This study looks at whether lifestyle changes can reduce the risk of liver cancer in people already at high risk. Researchers will track changes in bile acids, gut bacteria, and liver health in 90 adults aged 50-90. The goal is to see if simple adjustments can make a lasting diff…

This study tests whether an artificial intelligence (AI) model can predict how well liver cancer patients will respond to a combination of treatments, including a procedure called TACE, immunotherapy, and targeted therapy. Researchers will analyze medical images and other data fr…

This large French study will follow 1,810 adults receiving their first liver transplant to see if the way the donor liver is removed affects outcomes. The main focus is on avoiding artery and bile duct complications for three years after transplant. The goal is to identify the be…

This study will test whether an artificial intelligence (AI) model can help doctors decide between surgery and microwave ablation for people with early-stage liver cancer. The AI will analyze images from contrast-enhanced ultrasound and MRI scans to predict the risk of cancer ret…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This early-phase trial tests an artificial intelligence system that watches live video from pituitary tumor surgeries performed through the nose. The AI identifies anatomy, instruments, and surgical steps, displaying its analysis on tablets for the surgical team (not the lead sur…

This observational study will follow 40 adults with thymic abnormalities or myasthenia gravis (MG)-related antibodies to better understand how the disease develops and progresses. Researchers will analyze blood, thymus tissue, and muscle samples, along with clinical assessments, …

This study will follow 1,000 adults who have liver or bile duct surgery at one hospital in Italy. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand what affects recovery and long-term health after these opera…

This study collects blood and tissue samples from 110 adults with advanced lung, head and neck, or mesothelioma cancer. The samples are stored in a biobank to help scientists study cancer genes and find better ways to predict treatment outcomes. Participants do not receive any ex…

This study looks at whether non-diabetic patients who have pancreas surgery can safely avoid routine insulin afterward. About 290 adults will be randomly assigned to receive either standard insulin or no insulin after surgery. The goal is to see if skipping insulin keeps blood su…

This study aims to improve how doctors predict and monitor thyroid cancer by combining genetic testing of tumors with protein analysis from urine samples. Researchers will follow 100 newly diagnosed thyroid cancer patients to see if these markers can detect early signs of recurre…

This study looks at whether a thorough health assessment before liver surgery can help older patients (70+) have fewer serious complications and recover better. Researchers will give 242 participants a special geriatric evaluation that checks frailty, memory, nutrition, and daily…

This trial looks at whether keeping or removing a drainage tube (PTCD catheter) during pancreatic surgery leads to fewer complications. About 100 patients with jaundice from tumors will be randomly assigned to one of two groups. The main goal is to see which approach reduces seri…

This pilot study will test a new ultrasound probe and machine learning software to see if they can better visualize thyroid nodules compared to standard ultrasound. About 30 adults with known benign thyroid nodules will receive both types of scans. The goal is to improve detectio…

This study will examine stored tumor samples from 244 people diagnosed with biliary tract cancer in the last 15 years. Researchers will measure five specific markers (CLDN18.2, HER2, TROP2, PD-L1, and B7-H4) to see how common they are and how they relate to patient outcomes. The …

This study will enroll 200 patients scheduled for surgery to remove rare adrenal tumors called pheochromocytomas or paragangliomas (PPGL). Before surgery, researchers will use a model to predict the risk of severe blood pressure swings during the operation. During surgery, a real…

This study will use artificial intelligence to analyze CT scans and medical data from 400 liver cancer patients to predict who will respond to a common drug combination (atezolizumab and bevacizumab). The goal is to create a non-invasive tool that helps doctors choose the best tr…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test memory, attention, and other thinking skills before treatment and at 6, 12, and 24 months after. The goal is to learn how CAR-T therapy affects brain function …

This study will follow 1,100 people with advanced neuroendocrine tumors (a rare, slow-growing cancer) to see which treatments or treatment sequences cause the fewest long-term side effects. Researchers will track patients for up to 5 years, recording any side effects that last mo…

This study aims to learn if blood tests for cancer DNA (ctDNA) and patient-reported quality of life can help doctors predict how bile duct cancer will progress and whether treatments are working. Researchers will collect blood samples and surveys from 300 patients with curable or…

This study will create a registry of about 120 patients in Poland who have carcinoid heart disease, a rare complication of neuroendocrine tumors that damages heart valves. Researchers will collect medical records, echocardiograms, and lab results to better understand who develops…

This study watches 200 adults with intermediate-stage liver cancer to see which treatments doctors actually use and how long patients survive. It does not test a new drug or procedure. The goal is to learn from real-world care to help guide future treatment decisions.

This study tests whether a special catheter called TriNav can deliver more radiation beads (Y90 microspheres) to liver tumors while reducing exposure to healthy liver tissue. Twenty adults with unresectable liver tumors will receive the standard radioembolization procedure using …

This study aims to create detailed computer models, or 'virtual twins,' of people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). By analyzing data from over 7,700 adults, researchers hope to better understand how the disease progresses and predict who migh…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study is for young adults (ages 21-45) who had certain cancers as teens or young adults. Researchers are adapting a program that helps survivors manage their health after cancer treatment. The goal is to see if this program improves survivors' confidence and ability to handl…

This study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…

This study reviews medical records of 300 adults who had endoscopic or surgical removal of rectal tumors between 2015 and 2025. Researchers want to see if newer endoscopic methods are as safe and effective as traditional surgery. The goal is to help doctors choose the best approa…

This study tests whether personalized 3D liver models help surgeons plan major liver surgery more accurately. 25 adults having liver resection will get a 3D model before surgery. After surgery, the predicted and actual removed liver volumes are compared. The goal is to reduce the…

This study will watch how doctors use a special camera (endoscopic ultrasound) to diagnose suspected pancreatic or bile duct diseases in 2500 adults across Lombardy, Italy. The goal is to see how accurate the procedure is, how safe it is, and how quickly patients get a final diag…

This study looks at whether blood tests can predict how well liver cancer responds to a standard treatment called TACE. Researchers will collect blood samples from 60 adults with liver cancer before and after TACE, then compare the results with CT or MRI scans. The goal is to see…

This study aims to create a 3D model of the bile ducts using MRI and CT scans, along with an AI tool to help doctors guide a camera during a procedure called ERCP. The goal is to improve safety and accuracy. The study will use existing medical images from 100 adult patients who h…

This study looks back at medical records of 350 people with advanced non-small cell or small cell lung cancer who took anlotinib after their previous treatment stopped working. The goal is to see how well anlotinib works and how safe it is when used in later lines of therapy. The…

This study will follow 154 older adults with type 2 diabetes who are scheduled for liver tumor surgery. Researchers will measure brain glucose metabolism using a PET scan before surgery and then check for delirium (sudden confusion) for a week after. The goal is to see if lower b…

This study looks at whether a blood test that detects tiny bits of tumor DNA (called minimal residual disease) can predict if liver cancer will come back after surgery. Researchers will test 276 patients before and after surgery to see if the test can also identify who might bene…

This study will create a biobank by collecting blood, tissue, and bile samples from 300 adults with liver, bile duct, or pancreatic tumors, as well as from people with benign conditions and healthy volunteers. No experimental treatments or extra procedures are involved—samples ar…

This study looks at whether getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves outcomes for people with liver cancer. Researchers will review medical records of 200 patients in Austria to compare response rates, survival, and side effects …

This trial compares two techniques used when standard bile duct access fails during ERCP: pre-cut sphincterotomy and the double guidewire technique. Researchers will enroll 840 adults with difficult bile duct cannulation to see which method is safer and more successful. The goal …

This study looks at stored liver biopsy samples from 30 people with MASH (a fatty liver disease) to see if a protein test can predict who will develop liver cancer within 15 years. Half of the participants later got liver cancer, and half did not. Researchers will compare the pro…

This study aims to find out how often a rare genetic condition called alpha-1 antitrypsin deficiency (AATD) occurs in people who develop liver cancer (hepatocellular carcinoma) but do not have cirrhosis or other known causes like hepatitis or heavy drinking. Researchers will look…

This study will follow 75 adults with advanced liver cancer who are already receiving immune checkpoint inhibitors as part of their regular care. Researchers will track how long patients live and how long the cancer stays under control. The goal is to better understand the real-w…

This study reviews past medical records of 300 people who had surgery for a rare and aggressive bile duct cancer called hilar cholangiocarcinoma. It aims to see if also removing nearby blood vessels during the operation helps patients live longer and have fewer complications. The…

This study will look at how a single 30-minute bike ride changes levels of certain liver proteins (FGF21 and follistatin) in 12 people with liver cancer. Researchers want to understand how exercise affects the body in these patients, which could lead to better exercise recommenda…